Literature DB >> 34758609

Interferon α-induced SAMHD1 regulates human cultured megakaryocyte apoptosis and proplatelet formation.

Seema Bhatlekar1, Shancy Jacob1, Emilia Tugolukova1, Bhanu K Manne2, Yasuhiro Kosaka1, Phillipe Loher3, Ryan M O'Connell4, Vicente Planelles5, Matthew T Rondina6, Isidore Rigoutsos7, Paul F Bray8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34758609      PMCID: PMC8804568          DOI: 10.3324/haematol.2021.279864

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
Megakaryocyte (MK) growth, differentiation and maturation are required for thrombopoiesis and platelet production. Most studies of megakaryocytopoiesis have utilized in vitro culture systems expected to model a healthy human condition. However, consistent with the ability of MK to respond to inflammatory mediators, chronic inflammatory conditions often induce thrombocytosis, whereas acute inflammation can result in thrombocytopenia. Furthermore, there is an increasing awareness of the role MK play in innate and adaptive immunity.[1] Type 1 interferons (IFN-1), including IFNa, IFNb and INFω are a family of cytokines that bind to the IFN-1 receptor and trigger transcription of diverse genes. IFNinducible genes regulate resistance to viral infections, enhance innate and adaptive immunity, and modulate normal and tumor cell survival and death.[2] MK express the IFN-1 receptor that signals through Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) pathway in response to IFN-1 cytokines.[3] IFNa, an IFN-1 cytokine, has been effectively utilized in the treatment of myeloproliferative neoplasms and viral hepatitis. Thrombocytopenia is a common adverse effect of IFNa therapy that can require dose reduction. Although there are inconsistent reports regarding IFNa suppression of colony forming units of megakaryocyte progenitors (CFU-MK) in cultures of human CD34+ cells, there are consistent findings to support a mechanism of decreased platelet production rather than reduced platelet life span.[4-7] However, the molecular mechanisms regulating IFNa-induced decrease in platelet production and peripheral blood thrombocytopenia are poorly understood. The major conclusions in this report are (i) using genome-wide gene expression profiling we show that IFNa upregulates the expression of MK sterile a motif (SAM) and histidineaspartate (HD) domain containing deoxynucleoside triphosphate triphophohydrolase 1 (SAMHD1) and (ii) SAMHD1 expression inhibits cultured human MK proplatelet formation (PPF) and promotes apoptosis. This is the first identification of SAMHD1 in human MK and report of a dNTP hydrolase regulating platelet production. Interferona regulates platelet production. (A to E) CD34+ hematopoietic stem cells and progenitor cells were isolated by immunomagnetic separation from human umbilical cord blood. Cells were cultured for 13 days in stem cells expansion media supplemented with thrombopoietin that promotes megakaryocyte (MK) differentiation. 1,000 units/milliliter (U/mL) of human interferon α (INFα) and phosphate-buffered saline (PBS) (used as a negative control) was added at day 9 and further incubated until day 13. All assays mentioned in panels A to E were performed at day 13. (A) MK proplatelet formation (PPF) was counted blinded as to the IFNa treatment. At least 200 cells were counted per culture (n=4). (B) Representative images of day 13 cultured MK treated with PBS or IFNa. Treated MK were plated on fibrinogen on day 12 overnight, and fixed with 4% paraformaldehyde, stained with Alexa Fluor 488 Phalloidin (green) and a nuclear stain, DAPI (blue). Images were taken by a confocal microscope at 40X oil objective lens. (C) Platelet-like particles (PLP) were collected from IFNa or PBS-treated MK cultures and stained with APC labeled anti-CD41a antibody at 37°C for 10 minute and measured by flow cytometry (n=3). PLP were gated based on human peripheral blood platelets. (D) MK were stained with APC-labeled CD41a and PE-labeled CD42a antibodies, and CD41a+ CD42a+ MK (a marker for MK maturation) were assessed by flow cytometry (n=3). (E) Cultured MK treated with IFNa or PBS were stained with APC-labeled CD41a and propidium iodide, and ploidy was assessed by flow cytometry (n=3). The quantification of the ploidy distribution is shown on the y-axis by calculating the percentage of cells with 2n, 4n, 8n and 16n. Apoptotic population were gated out. Statistical significance was determined by two-tailed paired t-test (A to E). Error bars represent mean ± standard error of mean. (F) 25,000 units of murine IFNa or PBS (negative control) were administered intraperitoneally in wild-type mice for consecutive three days (n=5 per group). On day 4, mice blood was harvested by cardiac puncture and platelet count was measured by Hemavet. Statistical significance was determined by two-tailed unpaired t-test with Welch’s correction. Error bars represent mean ± standard error of mean. In order to pursue studies on the effects of inflammation on megakaryocytopoiesis, we used CD34+ hematopoietic stem cells derived from human umbilical vein cord blood. IFNa significantly decreased day 13 PPF and platelet-like particles (Figure 1A to C), but did not affect the percentages of MK or polyploidy (Figure 1D to E). Importantly, we also showed that exogenous IFNa induces thrombocytopenia in wild-type mice (Figure 1F), consistent with studies in immunodeficient mice.[4] In order to begin to understand how IFNa regulates latestage megakaryopoiesis and platelet production, we used an unbiased, transcriptome-wide approach and performed RNA sequencing (RNA-seq) on CD61-purified, day 13 cultured MK stimulated with IFNa. Our analyses identified 201 transcripts that were differentially expressed at a nominal significance threshold (P<0.05). Adjusting for multiple comparisons and setting a false discovery rate (FDR) threshold of <0.05, we found that 66 of the 201 transcripts were upregulated by IFNa (Online Supplementary Table S1). Increased mRNA expression in response to IFNa was validated by realtime polymerase chain reaction (PCR) analysis for all five genes tested (SAMHD1, PHF11, ISG20, IFITM3 and TAP2) (Online Supplementary Figure S1). Gene ontology analysis indicated that the differentially expressed genes were associated with the type 1 interferon signaling pathway, defense response to virus, and negative regulation of viral genome replication. Subsequent studies focused on SAMHD1, whose abundance increased more than 16-fold with IFNa induction (FDR=2.0x10-18) (Figure 2A). Figure 2B and C shows that IFNa treatment of cultured MK greatly increased the abundance of SAMHD1 mRNA and protein (n=3 independent biological replicates). SAMHD1 is a hydrolase, the activated form of which degrades the intracellular pool of deoxynucleoside triphosphates (dNTPase) into deoxynucleosides and inorganic triphosphates, and is known to restrict viral replication of the human immunodeficiency virus type-1.[8] In addition to viral restriction, SAMHD1 is required for cellular functions including replication fork progression, cell proliferation, apoptosis and DNA damage repair.[9] IFNa stimulation induces SAMHD1 expression in human monocytes,[10] astrocytes, microglia,[11] HEK293T and HeLa cells,[12] but there are no prior reports of SAMHD1 expression and/or function in MK or platelets.
Figure 1.

Interferona regulates platelet production. (A to E) CD34+ hematopoietic stem cells and progenitor cells were isolated by immunomagnetic separation from human umbilical cord blood. Cells were cultured for 13 days in stem cells expansion media supplemented with thrombopoietin that promotes megakaryocyte (MK) differentiation. 1,000 units/milliliter (U/mL) of human interferon α (INFα) and phosphate-buffered saline (PBS) (used as a negative control) was added at day 9 and further incubated until day 13. All assays mentioned in panels A to E were performed at day 13. (A) MK proplatelet formation (PPF) was counted blinded as to the IFNa treatment. At least 200 cells were counted per culture (n=4). (B) Representative images of day 13 cultured MK treated with PBS or IFNa. Treated MK were plated on fibrinogen on day 12 overnight, and fixed with 4% paraformaldehyde, stained with Alexa Fluor 488 Phalloidin (green) and a nuclear stain, DAPI (blue). Images were taken by a confocal microscope at 40X oil objective lens. (C) Platelet-like particles (PLP) were collected from IFNa or PBS-treated MK cultures and stained with APC labeled anti-CD41a antibody at 37°C for 10 minute and measured by flow cytometry (n=3). PLP were gated based on human peripheral blood platelets. (D) MK were stained with APC-labeled CD41a and PE-labeled CD42a antibodies, and CD41a+ CD42a+ MK (a marker for MK maturation) were assessed by flow cytometry (n=3). (E) Cultured MK treated with IFNa or PBS were stained with APC-labeled CD41a and propidium iodide, and ploidy was assessed by flow cytometry (n=3). The quantification of the ploidy distribution is shown on the y-axis by calculating the percentage of cells with 2n, 4n, 8n and 16n. Apoptotic population were gated out. Statistical significance was determined by two-tailed paired t-test (A to E). Error bars represent mean ± standard error of mean. (F) 25,000 units of murine IFNa or PBS (negative control) were administered intraperitoneally in wild-type mice for consecutive three days (n=5 per group). On day 4, mice blood was harvested by cardiac puncture and platelet count was measured by Hemavet. Statistical significance was determined by two-tailed unpaired t-test with Welch’s correction. Error bars represent mean ± standard error of mean.

Figure 2.

Interferon α upregulates. dNTP hydrolase enzyme SAMHD1 in cultured megakaryocytes. CD34+ hematopoietic stem cells and progenitor cells were isolated by immunomagnetic separation from human umbilical cord blood. Cells were cultured in megakaryocyte (MK) promoting conditions by supplementation with thrombopoietin for 13 days. 1,000 units per milliliter (U/mL) of interferon α (INFα) and phosphate-buffered saline (PBS) (negative control) was added in 3 independent cultures at day 13 for 8 hours. (Dose and time course studies were performed in Meg-01 to select optimal concentrations and times, data not shown). CD61+ MK were separated by immunomagnetic beads and total RNA was obtained by mirVana kit. RNA samples with RIN score of >8 were used for RNA sequencing. The library preparation was done using TruSeq standard total RNA sample preparation kit with RNA depletion (Illumina Inc.). RNA sequensing was performed using NextSeq500 instrument with read length of 50 basepair single-end read. On average 68.9 million reads were obtained from each sample and genome mapping was on average 94.5% for all samples. (A) Volcano plot shows the relationship between the P-values and the fold change in normalized expression for IFNa or PBS treated cultured human MK. Differentially expressed genes (false discovery rate [FDR] <0.05) on IFNa treatment was plotted. SAMHD1 is shown in red. (B) Real-time polymerase chain reaction analysis validates the upregulation of SAMHD1 in IFNa-treated CD61+ MK compared to PBS control. Actin was used as housekeeping gene. Log[2] fold change of SAMHD1 mRNA levels is plotted for IFNa vs. PBS control (n=3). Statistical significance was determined by one sample t-test. (C) Representative immunoblot shows increase in SAMHD1 protein in IFNa-treated MK compared to PBS control. Actin is used as loading control.

Platelet RNA And eXpression 1 (PRAX1) data[13] demonstrated that SAMHD1 transcript levels are negatively associated with platelet count in healthy human subjects (Figure 3A), suggesting a possible inhibitory role of SAMHD1 in platelet production. Since SAMHD1 modulates the intracellular levels of dNTP, we hypothesized that an increase in the abundance SAMHD1 upon IFNa stimulation leads to decreased MK proliferation, maturation and DNA synthesis (MK polyploidy). However, deletion of SAMHD1 by CRISPR/Cas9 gene editing in cultures promoting unilineage MK differentiation (Figure 3B) did not affect MK maturation (Online Supplementary ) or ploidy (Online Supplementary Figure 2C). This suggests SAMHD1 effects thrombopoiesis rather than megakaryocytopoiesis. Similar to Figure 1, IFNa stimulation caused a significant decrease in MK PPF MK without CRISPR modification (Figure 3C, first 2 bars). The effect of IFNa on PPF was abolished when SAMHD1 was deleted (Figure 3C, second 2 bars). Lastly, IFNa is well-established as pro-apoptotic. [2] MK must restrain apoptosis to survive and progress safely through PPF and platelet shedding.[14,15] Although viral infections induce MK apoptosis,[15] we are not aware of in vitro studies assessing IFNa-induced MK apoptosis. Under the culture conditions described in Figure 3C, we assessed annexin V binding as a measure of MK apoptosis, and observed a significant increase in response to IFNa stimulation (Figure 3D, first 2 bars). Next, because SAMHD1 also promotes apoptosis,[9] we tested the effects of SAMHD1 deletion on IFNa-induced MK apoptosis. Deletion of SAMHD1 caused a modest reduction in annexin V binding (Figure 3D, bar 1 vs. bar 3), and significantly reduced IFNa-induced MK annexin V binding (Figure 3D, compare bars 2 and 4), supporting a role for SAMHD1 as a mediator of IFNa-induced MK apoptosis.
Figure 3.

Interferon α-induced SAMHD1 expression regulates human megakaryocyte (MK) proplatelet formation and MK apoptosis. (A) Plot of Pearson correlation (R) between platelet count and SAMHD1 mRNA levels in 154 healthy donors. Dotted lines represent 95% confidence intervals. (B to D) CRISPR/Cas9 knock-down of SAMHD1 in CD34+ derived human umbilical cord cells were performed at day 3. Cells were cultured in MK differentiation promoting conditions, and treated with 1,000 U/mL interferon α (INFα) and phosphate-buffered saline (PBS) control. On day 13, MK treated with IFNa or PBS were assayed as mentioned below. (B) Representative immunoblot of SAMHD1 after CRISPR-Cas9 knock-down (denoted as “SAMHD1 cr” throughout the figure) in day 13 human CD34+ derived cultured MK with or without IFNa. Guide RNA not targeting known genes are used as negative control with or without IFNa (“neg cr” throughout the figure). Fold changes of densitometric quantification of SAMHD1 immunoblots, normalized to actin is shown on right (n=5). (C) The percentage of proplatelet formation (PPF) MK, scored blinded, for SAMHD1 cr vs neg cr, with or without IFNa is shown (n=6). (D) The mean fluorescence intensity (MFI) of annexin V binding (a marker of apoptosis-induced phosphatidylserine expression) on IFNa stimulation in SAMHD1 cr vs. neg cr MK, with or without IFNa is plotted (n=5). Statistical significance was determined by paired t-test (B to D). Error bars represent mean ± standard error of mean.

Interferon α upregulates. dNTP hydrolase enzyme SAMHD1 in cultured megakaryocytes. CD34+ hematopoietic stem cells and progenitor cells were isolated by immunomagnetic separation from human umbilical cord blood. Cells were cultured in megakaryocyte (MK) promoting conditions by supplementation with thrombopoietin for 13 days. 1,000 units per milliliter (U/mL) of interferon α (INFα) and phosphate-buffered saline (PBS) (negative control) was added in 3 independent cultures at day 13 for 8 hours. (Dose and time course studies were performed in Meg-01 to select optimal concentrations and times, data not shown). CD61+ MK were separated by immunomagnetic beads and total RNA was obtained by mirVana kit. RNA samples with RIN score of >8 were used for RNA sequencing. The library preparation was done using TruSeq standard total RNA sample preparation kit with RNA depletion (Illumina Inc.). RNA sequensing was performed using NextSeq500 instrument with read length of 50 basepair single-end read. On average 68.9 million reads were obtained from each sample and genome mapping was on average 94.5% for all samples. (A) Volcano plot shows the relationship between the P-values and the fold change in normalized expression for IFNa or PBS treated cultured human MK. Differentially expressed genes (false discovery rate [FDR] <0.05) on IFNa treatment was plotted. SAMHD1 is shown in red. (B) Real-time polymerase chain reaction analysis validates the upregulation of SAMHD1 in IFNa-treated CD61+ MK compared to PBS control. Actin was used as housekeeping gene. Log[2] fold change of SAMHD1 mRNA levels is plotted for IFNa vs. PBS control (n=3). Statistical significance was determined by one sample t-test. (C) Representative immunoblot shows increase in SAMHD1 protein in IFNa-treated MK compared to PBS control. Actin is used as loading control. Interferon α-induced SAMHD1 expression regulates human megakaryocyte (MK) proplatelet formation and MK apoptosis. (A) Plot of Pearson correlation (R) between platelet count and SAMHD1 mRNA levels in 154 healthy donors. Dotted lines represent 95% confidence intervals. (B to D) CRISPR/Cas9 knock-down of SAMHD1 in CD34+ derived human umbilical cord cells were performed at day 3. Cells were cultured in MK differentiation promoting conditions, and treated with 1,000 U/mL interferon α (INFα) and phosphate-buffered saline (PBS) control. On day 13, MK treated with IFNa or PBS were assayed as mentioned below. (B) Representative immunoblot of SAMHD1 after CRISPR-Cas9 knock-down (denoted as “SAMHD1 cr” throughout the figure) in day 13 human CD34+ derived cultured MK with or without IFNa. Guide RNA not targeting known genes are used as negative control with or without IFNa (“neg cr” throughout the figure). Fold changes of densitometric quantification of SAMHD1 immunoblots, normalized to actin is shown on right (n=5). (C) The percentage of proplatelet formation (PPF) MK, scored blinded, for SAMHD1 cr vs neg cr, with or without IFNa is shown (n=6). (D) The mean fluorescence intensity (MFI) of annexin V binding (a marker of apoptosis-induced phosphatidylserine expression) on IFNa stimulation in SAMHD1 cr vs. neg cr MK, with or without IFNa is plotted (n=5). Statistical significance was determined by paired t-test (B to D). Error bars represent mean ± standard error of mean. In summary, our study indicates that IFNa leads to reduced platelet production and thrombocytopenia through apoptosis, and that IFNa-induced SAMHD1 is at least partially responsible for these effects on latestage platelet production by MK. Prior work has shown that expression of three candidate MK transcription factors is inhibited by IFNa[4], and perhaps SAMHD1 is also regulated at a transcriptional level in MK. Post-transcriptional mechanisms may also be at play, since the enzymatic ability of SAMHD1 to maintain dNTP homeostasis in other cells requires protein phosphorylation. Future studies in MK will be need to address these issues.
  15 in total

1.  Interferon-induced sterile alpha motif and histidine/aspartic acid domain-containing protein 1 expression in astrocytes and microglia is mediated by microRNA-181a.

Authors:  Changzhong Jin; Xiaorong Peng; Fumin Liu; Linfang Cheng; Tiansheng Xie; Xiangyun Lu; Haibo Wu; Nanping Wu
Journal:  AIDS       Date:  2016-08-24       Impact factor: 4.177

2.  Expression and functionality of type I interferon receptor in the megakaryocytic lineage.

Authors:  S Negrotto; C J De Giusti; M J Lapponi; J Etulain; L Rivadeneyra; R G Pozner; R M Gomez; M Schattner
Journal:  J Thromb Haemost       Date:  2011-12       Impact factor: 5.824

3.  The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia.

Authors:  H Wadenvik; J Kutti; B Ridell; P Revesz; S Jacobsson; B Magnusson; J Westin; L Vilén
Journal:  Blood       Date:  1991-05-15       Impact factor: 22.113

Review 4.  Megakaryocytes as immune cells.

Authors:  Pierre Cunin; Peter A Nigrovic
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

5.  Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes.

Authors:  Akiko Yamane; Takanori Nakamura; Hidenori Suzuki; Mamoru Ito; Yasuyuki Ohnishi; Yasuo Ikeda; Yoshitaka Miyakawa
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

6.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.

Authors:  Nadine Laguette; Bijan Sobhian; Nicoletta Casartelli; Mathieu Ringeard; Christine Chable-Bessia; Emmanuel Ségéral; Ahmad Yatim; Stéphane Emiliani; Olivier Schwartz; Monsef Benkirane
Journal:  Nature       Date:  2011-05-25       Impact factor: 49.962

7.  SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons.

Authors:  Corine St Gelais; Suresh de Silva; Sarah M Amie; Christopher M Coleman; Heather Hoy; Joseph A Hollenbaugh; Baek Kim; Li Wu
Journal:  Retrovirology       Date:  2012-12-11       Impact factor: 4.602

8.  SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection.

Authors:  André Berger; Andreas F R Sommer; Jenny Zwarg; Matthias Hamdorf; Karin Welzel; Nicole Esly; Sylvia Panitz; Andreas Reuter; Irene Ramos; Asavari Jatiani; Lubbertus C F Mulder; Ana Fernandez-Sesma; Frank Rutsch; Viviana Simon; Renate König; Egbert Flory
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

9.  Anti-apoptotic BCL2L2 increases megakaryocyte proplatelet formation in cultures of human cord blood.

Authors:  Seema Bhatlekar; Indranil Basak; Leonard C Edelstein; Robert A Campbell; Cory R Lindsey; Joseph E Italiano; Andrew S Weyrich; Jesse W Rowley; Matthew T Rondina; Martha Sola-Visner; Paul F Bray
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

10.  Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c.

Authors:  Leonard C Edelstein; Lukas M Simon; Raúl Teruel Montoya; Michael Holinstat; Edward S Chen; Angela Bergeron; Xianguo Kong; Srikanth Nagalla; Narla Mohandas; David E Cohen; Jing-fei Dong; Chad Shaw; Paul F Bray
Journal:  Nat Med       Date:  2013-11-10       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.